Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 12, 2017 08:02 ET | Source: Mithra Pharmaceuticals

Mithra Pharmaceuticals: MITHRA'S NORTH AMERICAN ADVISORY BOARD FOR DONESTA® WILL MEET IN MIAMI, FLORIDA THE 20TH- 21ST JANUARY 2017

PRESS RELEASE Mithra's North american Advisory Board for Donesta® will meet in miami, Florida the 20th- 21st January 2017 Mithra has set up scientific advisory boards composed of...
January 12, 2017 06:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication

Top line results from the 172-patient trial to be reported in early 2018Data to support Pluristem’s planned Biologics License Application for marketing approval of PLX-PAD in the U.S. and Europe14...
January 12, 2017 04:15 ET | Source: HiberGene Diagnostics Ltd

HiberGene Completes Group B Streptococcus Study with National Maternity Hospital

DUBLIN, Ireland, Jan. 12, 2017 (GLOBE NEWSWIRE) -- A joint study conducted by Dublin-based molecular diagnostics manufacturer HiberGene and the National Maternity Hospital (NMH), Dublin has found...
January 12, 2017 01:30 ET | Source: Mithra Pharmaceuticals

Mithra Pharmaceuticals: MITHRA'S NORTH AMERICAN ADVISORY BOARD FOR DONESTA® WILL MEET IN MIAMI, FLORIDA THE 20TH- 21ST JANUARY 2017

PRESS RELEASE Mithra's North american Advisory Board for Donesta® will meet in miami, Florida the 20th- 21st January 2017 Mithra has set up scientific advisory boards composed of international...
January 12, 2017 00:55 ET | Source: Zion Market Research

Global Oral AntiDiabetic Drug Market will reach USD 35.91 Billion by 2022: Zion Market Research

Sarasota, FL, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Oral Antidiabetic Drug Market by Drug Category (Sulfonylureas, Meglitinides, Biguanides and...
January 11, 2017 11:48 ET | Source: Ablynx NV

ABLYNX INITIATES THE PHASE IIb "RESPIRE" STUDY OF ITS WHOLLY-OWNED, FIRST-IN-CLASS, INHALED ANTI-RSV NANOBODY, ALX-0171, FOR THE TREATMENT OF RSV INFECTIONS IN HOSPITALISED INFANTS

ALX-0171 is a first-in-class inhaled Nanobody® developed for the treatment of RSV infections ALX-0171 was safe and well tolerated in a Phase IIa study in hospitalised infants with a RSV infection ...
January 11, 2017 11:48 ET | Source: Ablynx NV

ABLYNX START DE FASE IIb "RESPIRE" STUDIE MET HAAR EIGEN, EERSTE-IN-ZIJN-KLASSE, GEÏNHALEERD ANTI-RSV NANOBODY, ALX-0171, VOOR DE BEHANDELING VAN RSV INFECTIES IN GEHOSPITALISEERDE BABY'S

ALX-0171 is een eerste-in-zijn-klasse geïnhaleerd Nanobody® ontwikkeld voor de behandeling van RSV infecties ALX-0171 was veilig en werd goed verdragen in een Fase IIa studie in...
January 11, 2017 10:58 ET | Source: Cancer Support Community

Cancer Support Community Advocates for Patients and Families in Washington, D.C.

WASHINGTON, Jan. 11, 2017 (GLOBE NEWSWIRE) -- The Cancer Support Community, in partnership with leading cancer advocacy and community health care organizations, is participating today in a series of...
January 11, 2017 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections

RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection Under FDA's Generating...
January 11, 2017 07:04 ET | Source: VECTURA GROUP PLC

Vectura Group plc: Pre-close update

Vectura Group plc Pre-close update Significant business development progress with year-end revenues in line with expectations Chippenham, UK - 11 January 2017: Vectura Group plc (LSE: VEC)...